{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:19:10Z","timestamp":1792887550879,"version":"4.5.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:00:00Z","timestamp":1707523200000},"content-version":"vor","delay-in-days":1654,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"vor","delay-in-days":61,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013220","name":"Ultragenyx Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013220","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["asbmr.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,12,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>In adults with X-linked hypophosphatemia (XLH), excess FGF23 impairs renal phosphate reabsorption and suppresses production of 1,25-dihydroxyvitamin D, resulting in chronic hypophosphatemia and persistent osteomalacia. Osteomalacia is associated with poor bone quality causing atraumatic fractures, pseudofractures, delayed fracture healing, and bone pain. Burosumab is a fully human monoclonal antibody against FGF23. UX023-CL304 is an ongoing, open-label, single-arm, phase 3 study investigating the efficacy of subcutaneous burosumab, 1.0\u2009mg\/kg administered every 4\u2009weeks, in improving osteomalacia in adults with XLH who have not been treated for at least 2\u2009years before enrollment. The primary endpoint was improvement in osteoid volume\/bone volume assessed by transiliac bone biopsies obtained at baseline and week 48. Additional assessments included serum phosphorus, markers of bone turnover, fracture\/pseudofracture healing, and safety. Fourteen subjects enrolled, 13 completed 48\u2009weeks, and 11 completed paired biopsies. All osteomalacia-related histomorphometric measures improved significantly at week 48 (mean percent change: osteoid volume\/bone volume, \u201354%, osteoid thickness, \u201332%, osteoid surface\/bone surface, \u201326%, [median] mineralization lag time, \u201383%). Mean serum phosphorus concentration averaged across the mid-point of the dose cycle between weeks 0 and 24 was 3.3\u2009mg\/dL, a 50% increase from 2.2\u2009mg\/dL at baseline. Markers of bone formation and resorption increased at week 48 (least squares [LS] mean increase: P1NP, +77%; CTx, +36%; both p\u2009&amp;lt;\u20090.0001). All subjects had one or more treatment-emergent adverse event (AE). Most AEs were mild to moderate in severity. Two subjects experienced serious AEs (migraine; paresthesia) that were unrelated to treatment and resolved. Eleven subjects had 18 biopsy procedure-related AEs: 14 for pain, two for itch, and one each for headache and bandage irritation. No deaths or incidents of hyperphosphatemia occurred. In conclusion, by normalizing phosphate homeostasis, burosumab significantly improved osteomalacia in adults with XLH, which likely explains the improved fracture healing and amelioration of skeletal complications. \u00a9 2019 The Authors. Journal of Bone and Mineral Research published by American Society for Bone and Mineral Research.<\/jats:p>","DOI":"10.1002\/jbmr.3843","type":"journal-article","created":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T20:03:57Z","timestamp":1564689837000},"page":"2183-2191","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":134,"title":["Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X-Linked Hypophosphatemia: A Phase 3, Single-Arm, International Trial"],"prefix":"10.1093","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6973-5679","authenticated-orcid":false,"given":"Karl L","family":"Insogna","sequence":"first","affiliation":[{"name":"Department of Internal Medicine Yale School of Medicine New Haven CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6261-0360","authenticated-orcid":false,"given":"Frank","family":"Rauch","sequence":"additional","affiliation":[{"name":"Genetics Unit, Shriners Hospital for Children and McGill University Montreal QC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kamenick\u00fd","sequence":"additional","affiliation":[{"name":"APHP, Department of Endocrinology and Reproductive Diseases, Bic\u00eatre Paris Sud Hospital Le Kremlin Bic\u00eatre France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Endocrinology & Nephrology The University of Tokyo Hospital Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuo","family":"Kubota","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Osaka University Hospital Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akie","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Hokkaido University Hospital Hokkaido Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Ultragenyx Pharmaceutical Inc. Novato CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Mealiffe","sequence":"additional","affiliation":[{"name":"Ultragenyx Pharmaceutical Inc. Novato CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"San Martin","sequence":"additional","affiliation":[{"name":"Ultragenyx Pharmaceutical Inc. Novato CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony A","family":"Portale","sequence":"additional","affiliation":[{"name":"Division of Pediatric Nephrology University of California San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,8,1]]},"reference":[{"issue":"7","key":"2024021014405868600_jbmr3843-bib-0001","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/jbmr.340","article-title":"A clinician's guide to X-linked hypophosphatemia","volume":"26","author":"Carpenter","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2024021014405868600_jbmr3843-bib-0002","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1530\/EC-13-0103","article-title":"Therapeutic management of hypophosphatemic rickets from infancy to adulthood","volume":"3","author":"Linglart","year":"2014","journal-title":"Endocr Connect"},{"issue":"5","key":"2024021014405868600_jbmr3843-bib-0003","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s10545-018-0147-6","article-title":"Outcome of adult patients with X-linked hypophosphatemia caused by PHEX gene mutations","volume":"41","author":"Chesher","year":"2018","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"2024021014405868600_jbmr3843-bib-0004","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1530\/EJE-15-0661","article-title":"Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms","volume":"174","author":"Che","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2024021014405868600_jbmr3843-bib-0005","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1148\/radiology.171.2.2539609","article-title":"X-linked hypophosphatemia in adults: prevalence of skeletal radiographic and scintigraphic features","volume":"171","author":"Hardy","year":"1989","journal-title":"Radiology"},{"issue":"3","key":"2024021014405868600_jbmr3843-bib-0006","first-page":"879","article-title":"A prospective trial of phosphate and 1,25-dihydroxyvitamin D3 therapy in symptomatic adults with X-linked hypophosphatemic rickets","volume":"75","author":"Sullivan","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"issue":"18","key":"2024021014405868600_jbmr3843-bib-0007","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJM198010303031802","article-title":"Bone response to phosphate salts, ergocalciferol, and calcitriol in hypophosphatemic vitamin D-resistant rickets","volume":"303","author":"Glorieux","year":"1980","journal-title":"N Engl J Med"},{"issue":"6","key":"2024021014405868600_jbmr3843-bib-0008","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1172\/JCI111900","article-title":"Healing of bone disease in X-linked hypophosphatemic rickets\/osteomalacia. Induction and maintenance with phosphorus and calcitriol","volume":"75","author":"Harrell","year":"1985","journal-title":"J Clin Invest"},{"issue":"2","key":"2024021014405868600_jbmr3843-bib-0009","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1359\/jbmr.090728","article-title":"Bone mineralization defects and vitamin D deficiency: Histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675\u2009patients","volume":"25","author":"Priemel","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2024021014405868600_jbmr3843-bib-0010","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s00393-013-1285-8","article-title":"Metabolic bone disease osteomalacia","volume":"73","author":"Reuss-Borst","year":"2014","journal-title":"Z Rheumatol"},{"issue":"6","key":"2024021014405868600_jbmr3843-bib-0011","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s40265-018-0905-7","article-title":"Burosumab: first global approval","volume":"76","author":"Lamb","year":"2018","journal-title":"Drugs"},{"issue":"8","key":"2024021014405868600_jbmr3843-bib-0012","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/jbmr.3475","article-title":"A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: Week 24 primary analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2024021014405868600_jbmr3843-bib-0013","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","article-title":"Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period","volume":"105","author":"Portale","year":"2019","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"2024021014405868600_jbmr3843-bib-0014","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S8756-3282(99)00257-4","article-title":"Normative data for iliac bone histomorphometry in growing children","volume":"26","author":"Glorieux","year":"2000","journal-title":"Bone"},{"issue":"2","key":"2024021014405868600_jbmr3843-bib-0015","first-page":"129","article-title":"Pain assessment: global use of the brief pain inventory","volume":"23","author":"Cleeland","year":"1994","journal-title":"Ann Acad Med Singapore"},{"issue":"1","key":"2024021014405868600_jbmr3843-bib-0016","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jbmr.1805","article-title":"Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry nomenclature committee","volume":"28","author":"Dempster","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2024021014405868600_jbmr3843-bib-0017","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00002508-200409000-00005","article-title":"Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain","volume":"20","author":"Keller","year":"2004","journal-title":"Clin J Pain"},{"key":"2024021014405868600_jbmr3843-bib-0018","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/978-1-4419-9893-4_11","volume-title":"Brief Fatigue Inventory. STOP, THAT and One Hundred Other Sleep Scales","author":"Shahid","year":"2011"},{"issue":"21","key":"2024021014405868600_jbmr3843-bib-0019","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab therapy in children with X-linked hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N Engl J Med."},{"issue":"10189","key":"2024021014405868600_jbmr3843-bib-0020","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"2024021014405868600_jbmr3843-bib-0021","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S2213-8587(18)30338-3","article-title":"Efficacy and safety of burosumab in children aged 1\u20134\u2009years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial","volume":"7","author":"Whyte","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"2","key":"2024021014405868600_jbmr3843-bib-0022","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0169-6009(90)90058-N","article-title":"Bone histomorphometric reference values in 88 normal Italian subjects","volume":"11","author":"Ballanti","year":"1990","journal-title":"Bone Miner"},{"issue":"2","key":"2024021014405868600_jbmr3843-bib-0023","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/jbmr.5650030203","article-title":"Static and tetracycline-based bone histomorphometric data from 34 normal postmenopausal females","volume":"3","author":"Recker","year":"1988","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2024021014405868600_jbmr3843-bib-0024","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1530\/EJE-15-0515","article-title":"Hereditary hypophosphatemia in Norway; a retrospective population-based study of genotypes, phenotypes and treatment complications","volume":"174","author":"Rafaelsen","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"2024021014405868600_jbmr3843-bib-0025","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1210\/JC.2015-2199","article-title":"Conventional therapy in adults with X-linked hypophosphatemia: effects on Enthesopathy and dental disease","volume":"100","author":"Connor","year":"2015","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jbmr.3843","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jbmr.3843","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/34\/12\/2183\/56653387\/jbmr3843.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/34\/12\/2183\/56653387\/jbmr3843.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T15:04:43Z","timestamp":1710342283000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/34\/12\/2183-2191\/7380845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,1]]},"references-count":25,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,8,1]]},"published-print":{"date-parts":[[2019,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.3843","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,12,1]]},"published":{"date-parts":[[2019,8,1]]},"assertion":[{"value":"2019-04-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}